Literature DB >> 8894139

Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.

X Yu1, J Schøller, N T Foged.   

Abstract

Treatment of osteoblasts by either parathyroid hormone (PTH) or bisphosphonate can affect their regulation of the bone-resorbing activity of osteoclasts in vitro, leading to increased and decreased resorption, respectively. To address this issue, we have examined the interaction between the effects of PTH and bisphosphonate on the regulation of osteoclast activity by the PTH-responsive osteoblast-like cell line UMR-106. When rat osteoclasts were cocultured with UMR-106 cells on bovine bone slices in the presence of 10(-8) mol/L PTH, the number of resorption pits was increased 4.2-fold, whereas the addition of UMR-106 cells or PTH alone had no effect. Pretreatment of the UMR-106 cells for 5 min with increasing concentrations of either of the bisphosphonates, clodronate, and ibandronate before coculture with osteoclasts in 10(-8) mol/L PTH, caused a dose-dependent reduction in the formation of resorption pits, reaching the maximal inhibition level (60%-75% below the control) at approximately 10(-9) mol/L clodronate and 10(-11) mol/L ibandronate. Addition of conditioned medium (CM) from untreated UMR-106 cells to rat osteoclasts had no effect on pit formation, whereas CM from UMR-106 cells pretreated with ibandronate reduced the osteoclastic bone resorption by approximately 40%. However, this effect was abolished by the subsequent culture of the ibandronate-pretreated UMR-106 cells in 10(-8) mol/L PTH before harvesting the CM, because both this CM and CM from non-pretreated UMR-106 cells cultured in 10(-8) mol/L PTH caused an approximately 75% increase in pit formation when added to rat osteoclasts. In conclusion, osteoclastic bone resorption can be directly affected independently as well as at the same time by the ibandronate-induced osteoclast-inhibiting factor and the PTH-induced osteoclast-stimulating factor. The final level of bone resorption depends on the relative concentration of these two factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894139     DOI: 10.1016/s8756-3282(96)00184-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.

Authors:  H J Lehmann; U Mouritzen; S Christgau; P A C Cloos; C Christiansen
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Modeling the interaction of seven bisphosphonates with the hydroxyapatite(100) face.

Authors:  Chunyu Chen; Mingzhu Xia; Lei Wu; Chao Zhou; Fengyun Wang
Journal:  J Mol Model       Date:  2012-03-27       Impact factor: 1.810

3.  Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.

Authors:  Han Qiao; Ting-yu Wang; Wei Yan; An Qin; Qi-ming Fan; Xiu-guo Han; Yu-gang Wang; Ting-ting Tang
Journal:  Acta Pharmacol Sin       Date:  2015-08-03       Impact factor: 6.150

4.  Modulation of murine bone marrow-derived CFU-F and CFU-OB by in vivo bisphosphonate and fluoride treatments.

Authors:  M-Y Chou; D Yan; T Jafarov; E T Everett
Journal:  Orthod Craniofac Res       Date:  2009-05       Impact factor: 1.826

5.  Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.

Authors:  P S Mackie; J L Fisher; H Zhou; P F Choong
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.